Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Jeyanthi Ramanarayanan"'
Publikováno v:
Advances in Lung Cancer. 11:31-44
Autor:
Myron S. Czuczman, Jeyanthi Ramanarayanan, Asher Chanan-Khan, Francisco J. Hernandez-Ilizaliturri
Publikováno v:
British Journal of Haematology. 127:519-530
New strategies have evolved in the treatment of patients with non-Hodgkin's lymphoma (NHL). Anti-sense oligonucleotides (ASO) and monoclonal antibody (mAb) therapy, though proven to be safe and effective, have not demonstrated to be curative when use
Publikováno v:
Clinical advances in hematologyoncology : HO. 6(3)
Autor:
Ganapathy S, Krishnan, Vijay, Chaudhary, Anas, Al-Janadi, Jeyanthi, Ramanarayanan, Karl J, D'Silva
Publikováno v:
Annals of transplantation. 13(1)
Carmustine (BCNU), 1, 3-bis (2-chloroethyl)-1-nitosourea, is an alkylating agent which is commonly used as a part of conditioning regimen for autologous peripheral blood stem cell transplantation. Despite the widespread use of BCNU therapy in adults,
Publikováno v:
Hematology (Amsterdam, Netherlands). 12(6)
Imatinib, a selective ABL kinase inhibitor has improved therapeutic outcome in patients with Philadelphia positive chronic or acute leukemia. In the present study, we describe a 56-year-old male with Philadelphia chromosome positive acute lymphocytic
Publikováno v:
JOP : Journal of the pancreas. 8(1)
Acute drug induced hepatitis has not been commonly associated with epidermal growth factor receptor (EGFR) inhibitors. Hepatotoxicity seen with erlotinib, a small molecule tyrosine kinase inhibitor to EGFR, is usually transient with mild elevation of
Autor:
Sheila N.J. Sait, Philip L. McCarthy, Jeyanthi Ramanarayanan, Lauren M. Dunford, Maria R. Baer, William Lawrence
Publikováno v:
Leukemia research. 30(6)
Recent improved treatments for lymphoid malignancies produce more long-term survivors, yet increase the risk for secondary malignancies. Therapy-related myelodysplasia and acute myeloid leukemia are well described, but secondary chronic myeloid leuke
Autor:
Jeyanthi, Ramanarayanan, Francisco J, Hernandez-Ilizaliturri, Asher, Chanan-Khan, Myron S, Czuczman
Publikováno v:
British journal of haematology. 127(5)
New strategies have evolved in the treatment of patients with non-Hodgkin's lymphoma (NHL). Anti-sense oligonucleotides (ASO) and monoclonal antibody (mAb) therapy, though proven to be safe and effective, have not demonstrated to be curative when use
Autor:
Jeffrey VanDeusen, Ganapathy S. Krishnan, Elizabeth Ann Whitt, Doug Smith, Debbie Elaine Bihl, Ralph W. Roach, Stacie Daugherty, Jeyanthi Ramanarayanan, Monica Copp
Publikováno v:
Journal of Clinical Oncology. 32:e20508-e20508
e20508 Background: The completion of advance directives (AD) and the discussion of a patient’s end of life goals result in a more patient-centered approach to care. The Adena Cancer Center develope...
Publikováno v:
Journal of Clinical Oncology. 27:7093-7093
7093 Background: Tumor necrosis factor-alpha (TNF-alpha) enhances tumor growth and mediates cancer-related inflammatory symptoms by inducing secretion of cytokines. Anti-TNF approaches have been evaluated in pilot studies for cancer treatment and for